Company intelligence / Profile preview

Nexturn Bio

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

Nexturn Bio is a Korean biotech subsidiary of Nexturn Bioscience that is building a pipeline of miRNA-based therapeutics through a strategic 50% stake in RosVivo Therapeutics; lead asset RSVI-301 for diabetes and additional programs for COVID-19 and metabolic/gastrointestinal diseases have shown promising pre-clinical animal data but had not yet entered clinical trials at the time of the latest public disclosures.[2][3][4]

Therapeutic areas: EndocrinologyInfectious DiseasesGastroenterology
Modalities: RNA therapy
Industry: Biotech

Partnerships

RosVivo Therapeutics[2][3][4]

Beyond the preview

Go deeper on Nexturn Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nexturn Bio.

Explore the full profile